The Food and Drug Administration's laundry list for Arena Pharmaceuticals
Now? Maybe not.
In an announcement highlighting layoffs -- a necessary evil of not having revenue streaming in -- Arena said that the FDA had added a couple of items to its to-do list since the last update.
The FDA had three major issues with lorcaserin. The one questioning the diagnosis of mammary tumors in rats seems easy to clear up. Arena has hired five independent pathologists to give their opinion of whether the tumors are benign or malignant.
Arena believes the rats get mammary tumors because of an increase in prolactin, which isn't relevant to humans. In addition to a three-month study, the "FDA requested that Arena consider performing a separate 12-month study." The FDA can't force a company to do an experiment, as far as I know, but if the agency is asking the Arena to consider it, I'd think doing so might be a good idea.
The third item has to do with proving that brain tumors seen in male rats aren't a concern. This one seems on track, although it remains to be seen whether the data comparing levels in human's spinal fluid will be enough to convince the FDA that the concentration in the brain isn't a problem.
It seems the FDA has added a fourth item to the list, though you wouldn't know it from Arena's press release since it just snuck the item onto the paragraph discussing the third problem. The agency asked Arena to run additional experiments to "characterize lorcaserin's activity at the 5-HT2B receptor to further assess the risk of valvulopathy." The heart valve problem, valvulopathy, was an issue with fenfluramine -- the fen part of Wyeth's fen-phen, which is related to lorcaserin. We can probably thank heart problems with Abbott Labs'
Hitting the end-of-the-year goal likely depends on whether Arena will have to do the 12-month study, which would obviously push it into 2012. In a rather confusing press release, the company said in the same paragraph that is believes "that it can resubmit the lorcaserin NDA by the end of 2011" and that "it is possible that certain activities may be required that could impact the timeline for resubmission."
Waiting until 2012 could potentially put the company third in the race for the next obesity drug; Orexigen's
Of course, getting the drug approved is most important. If investors get an inkling that management is trying to cut corners, I'd run.
Interested in keeping track of Arena as it tries to get lorcaserin approved? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Arena.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Motley Fool Alpha owns shares of Abbott Laboratories. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.
More from The Motley Fool
Here's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November
A robust clinical-stage pipeline helped investors forget about Arena's ill-fated weight-loss drug.
3 Top Diabetes Stocks to Buy Now
The diabetes market is growing. And these stocks are poised to grow with it.
The Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October
You could say that Arena "posterized" Wall Street in October and was rewarded for it.